Vivalis Expands R&D Capacities And Moves Into A New Facility
NANTES, FRANCE--(Marketwire - June 23, 2010) -
| Highlighted Links |
companynewsgroup Home Page |
This new 3,300 m² (35,520 ft2) facility is dedicated to R&D activities and support functions. The project was initiated at the end of 2008 and integrates all research teams onto the same site, which is adjacent to Vivalis' existing 1,500 m² (16,150 ft2) cGMP bioproduction facility, completed in 2005.
The new building houses state-of-the-art equipment used for biologics research and the construction has been governed by an environmentally responsible approach, being designed to use 25% less energy than our current bioproduction facility completed five years ago. With a total investment of 6.5M€ as budgeted (5.5M€ for the facility and approximately 1M€ for equipment), the facility was financed by state and local entities (DIACT, Region Pays de Loire, Departement of Loire Atlantique and Nantes Métropole for a total of 2.4M€), bank loans (2.5M€) and VIVALIS (1.6M€).
With this new facility VIVALIS will be able to accelerate its development projects while improving the working environment and conditions of its employees.
"We are very pleased to move into these new facilities that give us the ability to regroup the teams that were spread over several locations following the rapid expansion of our workforce. We are very proud of being able to offer our researchers optimal conditions to conduct their research. We now have two locations in Nantes totaling over 4,800 m² (51,700 ft2) located on one site and dedicated to research and biomanufacturing," said Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.
**********************
Next financial press release:
21 July 2010, after NYSE Euronext market closing: Second quarter 2010 revenues
About VIVALIS (www.vivalis.com)
VIVALIS (Euronext code: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:
1. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines and monoclonal antibodies. VIVALIS receives upfront fees, milestone payments and royalties on licensees' net sales.
2. Through the Humalex® platform, VIVALIS offers customers solutions for the generation, development and production of human antibodies. VIVALIS receives upfront fees, milestone payments and royalties on licensees' net sales.
3. A portfolio of proprietary products in the area of vaccines and anti- viral molecules (hepatitis C).
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (ca. 1,500 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.
+-------------------------+-+ |VIVALIS | | +-------------------------+-+ |Listed on Euronext Paris | | |– Compartment C of NYSE | | |Euronext | | +-------------------------+-+ |Reuters: VLS.PA – | | |Bloomberg: VLS FP | | +-------------------------+-+ |Included in NYSE | | |Euronext’s SBF 250, CAC | | |Small 90 and Next Biotech| | |indexes | | +-------------------------+-+ +-------------------------+-+Contacts
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communications agency
Steve Grobet / Pierre Laurent
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.
This information is provided by HUGIN